ADC Therapeutics (ADCT) Net Cash Flow (2020 - 2026)

ADC Therapeutics (ADCT) has reported Net Cash Flow for 7 consecutive years, with -$30.3 million the latest figure, recorded in Q1 2026.

• Quarterly Net Cash Flow rose 46.16% year-over-year to -$30.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $36.2 million (up 191.09% YoY) and the FY2025 annual result came in at $10.2 million, up 136.77% from the prior year.
• Net Cash Flow slipped to -$30.3 million in Q1 2026 per ADCT's latest filing, from $26.6 million in the prior quarter.
• Over the last five years, Net Cash Flow for ADCT reached as high as $69.7 million in Q2 2025 and fell as low as -$56.3 million in Q1 2025.
• A 5-year average of -$13.9 million and a median of -$29.8 million in 2025 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2023 — Net Cash Flow plunged 958.92% — and 2025, when it jumped 215.45%.
• Year by year, Net Cash Flow stood at -$54.7 million in 2022, then soared by 41.53% to -$32.0 million in 2023, then increased by 27.84% to -$23.1 million in 2024, then soared by 215.45% to $26.6 million in 2025, then tumbled by 213.9% to -$30.3 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$30.3 million, $26.6 million, and -$29.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.